Auxilium Pharmaceuticals Inc

Auxilium Pharmaceuticals — Investor Presentation (October 2008)

44 slides from Auxilium Pharmaceuticals's investor presentation, Oct 30, 2008

  1. Slide 1: October/November

    Exhibit 99.1 October/November

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Safe Harbor Statement We will make various remarks during this presentation that constitute “forward-looking statements” for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding the pricing, time to ma

  3. Slide 3: Slide 3

  4. Slide 4: Auxilium Pharmaceuticals, Inc.

    Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) • Specialty biopharmaceutical company focused on Urologists, Endocrinologists, Orthopedists and certain PCPs • Founded in 1999 • Headquarters in Malvern, Pa. – Manufacturing in Horsham, Pa. – Approximately 33

  5. Slide 5: Broad Maturing Pipeline

    Broad Maturing Pipeline Late Research Market Phase III Phase II Phase I Hypogonadism Dupuytren’s Contracture Peyronie’s Disease Frozen Shoulder Syndrome Overactive Bladder Pain (fentanyl) Broad Maturing Pipeline Note: Worldwide rights for all products available, except Testim where ex -U.S. rights h

  6. Slide 6: Anticipated News Flow Events

    Anticipated News Flow Events 5 Q409 Q309 Q209 Q109 2010 Anticipated News Flow Events End of 2009: • XIAFLEX- Results of Peyronie's Phase IIb Study H109: • XIAFLEX- Open Label Dupuytren ’ s Contracture Safety Data Early 2009: • XIAFLEX- File BLA for Dupuytren's Contracture Early 2010 XIAFLEX – FDA Ap

  7. Slide 7: XIAFLEX- Unique, Late-Stage, Blockbuster Opportunity

    XIAFLEX- Unique, Late-Stage, Blockbuster Opportunity XIAFLEX- Unique, Late-Stage, Blockbuster Opportunity • Potential to be first effective non-surgical treatment for two high unmet needs – Dupuytren’s contracture – Peyronie’s disease • Well-characterized mode of action • Worldwide rights offer opti

  8. Slide 8: Dupuytren's Contracture—a Debilitating Condition

    Dupuytren’s Contracture—a Debilitating Condition Dupuytren’s Contracture—a Debilitating Condition • Excessive collagen deposition • Nodules represent early, active form • Cords develop over time, are palpable, and result in contractures • Debilitating effect on quality of life • Surgery may be reser

  9. Slide 9: Current Treatment Options Are Invasive or Ineffective

    Current Treatment Options Are Invasive or Ineffective Current Treatment Options Are Invasive or Ineffective • Surgery • Non-surgical options – Splinting – Physical therapy – Corticosteroids • Needle fasciotomy/ aponeurotomy • Amputation

  10. Slide 10: Dupuytren's Contracture—Unmet Medical Need

    Dupuytren’s Contracture—Unmet Medical Need Dupuytren’s Contracture—Unmet Medical Need • Disease prevalence is estimated at 3%-6% among adult Caucasians, but occurs in all populations • Higher prevalence in patients of northern-European descent • Hereditary component in approximately 40% of patients

  11. Slide 11: XIAFLEX—Potential to Revolutionize Treatment for Dupuytren's Contracture

    XIAFLEX—Potential to Revolutionize Treatment for Dupuytren’s Contracture XIAFLEX—Potential to Revolutionize Treatment for Dupuytren’s Contracture

  12. Slide 12: XIAFLEX—Potential to Revolutionize Treatment for Dupuytren's Contracture

    XIAFLEX—Potential to Revolutionize Treatment for Dupuytren’s Contracture XIAFLEX—Potential to Revolutionize Treatment for Dupuytren’s Contracture

  13. Slide 13: CORD I Design

    CORD I Design CORD I Design • Largest ever double-blind, placebo-controlled trial in Dupuytren’s contracture – randomized in 2:1 ratio of active to placebo – enrolled a 2:1 ratio of MP:PIP – enrolled 1:1 ratio of less severe to more severe joints • Primary endpoint is reduction in contracture to wit

  14. Slide 14: Primary Endpoint Outcome Compares Favorably To Surgery

    Primary Endpoint Outcome Compares Favorably To Surgery Primary Endpoint Outcome Compares Favorably To Surgery

  15. Slide 15: 4 Out Of 5 Dupuytren's Contracture Patients Improved By 50%

    4 Out Of 5 Dupuytren’s Contracture Patients Improved By 50% 4 Out Of 5 Dupuytren’s Contracture Patients Improved By 50%

  16. Slide 16: Contracture Reduction By Degrees Indicates Average XIAFLEX Patient Achieves ~10°

    Contracture Reduction By Degrees Indicates Average XIAFLEX Patient Achieves ~10° Of Contracture Contracture Reduction By Degrees Indicates Average XIAFLEX Patient Achieves ~10° Of Contracture

  17. Slide 17: XIAFLEX Phase III AE and SAE Rates Should Compare Favorably To Surgical Complications

    XIAFLEX Phase III AE and SAE Rates Should Compare Favorably To Surgical Complications XIAFLEX Phase III AE and SAE Rates Should Compare Favorably To Surgical Complications Serious Adverse Events Number Rate/Inj. Tendon / Ligament*: Confirmed Tendon Rupture 0.12% Ligament Injury 0.04% Total Tendon /

  18. Slide 18: CORD I Key Takeaways

    CORD I Key Takeaways CORD I Key Takeaways • Primary endpoint of 5° reached in 64% of patients (p<0.001) – 25 of 26 endpoints met with statistical significance of <0.001, 1 of 26 was met with a p-value = 0.002 – Of the 73 patients who didn’t respond, 44 received less than 3 injections and 25 had no p

  19. Slide 19: Dupuytren's Commercial Opportunity

    Dupuytren’s Commercial Opportunity We believe: • There is a pent-up demand for non-surgical therapy • Surgeons and patients prefer non-invasive treatment • Each patient on average has 2.2 joints which will require treatment; about half have contractures in both hands • Early data indicates on averag

  20. Slide 20: Market Research Performed – Dupuytren's

    Market Research Performed – Dupuytren’s Market Research Performed – Dupuytren’s • Multiple prevalence data sets proved to be highly variable in numbers of patients • Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Dupuytren’s contracture • A combined 571

  21. Slide 21: At least 240,000 Dupuytren's Candidates In U.S. & Europe Annually

    At least 240,000 Dupuytren’s Candidates In U.S. & Europe Annually Patients Seeking Treatment ~1,030,000 No Prior Surgery ~540,000 Had Surgery Previously ~490,000 Watchful Waiting ~270,000 Medical/ Surgical Treatment ~270,000 Medical/ Surgical Treatment ~125,000 Watchful Wait/ In Follow Up ~365,000 X

  22. Slide 22: XIAFLEX I.P. Position for Dupuytren's Contracture

    XIAFLEX I.P. Position for Dupuytren’s Contracture XIAFLEX I.P. Position for Dupuytren’s Contracture • U.S. Orphan Drug Exclusivity granted on May 23, 1996 for 7 years post approval • Market Exclusivity expected in EU for 10 years post - approval –Data protection granted for 8 years • Method of Use P

  23. Slide 23: Expected Pathway to BLA Filing in Early 2009

    Expected Pathway to BLA Filing in Early 2009 Expected Pathway to BLA Filing in Early 2009 • Complete 12 month open-label safety follow up from >100 CORD I patients originally randomized to XIAFLEX • Complete open-label CORD II and JOINT I/II trials to attain 1,000 patient exposure data • Finalize BL

  24. Slide 24: Peyronie's Disease—a Devastating Disorder

    Peyronie’s Disease—a Devastating Disorder 1. Smith BH. Am J Clin Pathol . 1966;45:670-678. 2. Somers KD, Dawson DM. J Urol . 1997;157:311-315. Peyronie’s Disease—a Devastating Disorder • Scarring phenomenon affecting the tunica albuginea • Plaques show excessive collagen deposition • Potential Sympt

  25. Slide 25: Epidemiology—Peyronie's Disease

    Epidemiology—Peyronie’s Disease Epidemiology—Peyronie’s Disease • Prevalence of Peyronie’s disease is estimated at 1 in 20 adult men – Actual prevalence higher based on autopsies • Prevalence rate increases with age – The average age of disease onset is 53 years • High association with other disease

  26. Slide 26: Current Treatment—Surgical

    Current Treatment—Surgical Current Treatment—Surgical • The goal of surgery is simply to make the two sides of the penis equal in size • Graft or prosthetic may be required • Cost of surgery in U.S. is ~$10-12K

  27. Slide 27: Peyronie's Disease—Unapproved Treatments Have Been Used With Little Reported Success

    Peyronie’s Disease—Unapproved Treatments Have Been Used With Little Reported Success Peyronie’s Disease—Unapproved Treatments Have Been Used With Little Reported Success • Verapamil • Vitamin E • Colchicine • Potassium aminobenzoate (Potaba) • Tamoxifen • Interferon alpha-2a • Corticosteroids • Ener

  28. Slide 28: Promising Phase II Results: Patients With 25% Reduction in the Angle of Deviation

    Promising Phase II Results: Patients With 25% Reduction in the Angle of Deviation Promising Phase II Results: Patients With 25% Reduction in the Angle of Deviation Study 1030 58% 53% 35% 0% 20% 40% 60% 80% 100% Month 3 Month 6 Month 9 Study 1035 50% 100% 100% 89% 0% 20% 40% 60% 80% 100% Week 6 Month

  29. Slide 29: Peyronie's Phase IIb Study Enrolling Patients

    Peyronie’s Phase IIb Study Enrolling Patients Peyronie’s Phase IIb Study Enrolling Patients • Study designed to assess the safety and efficacy of XIAFLEX. – XIAFLEX will be administered two times a week every six weeks for up to three treatment cycles (2 x 3) – ~120 patients – ~11 U.S. sites • Patie

  30. Slide 30: Peyronie's Phase IIb Study Design

    Peyronie’s Phase IIb Study Design Peyronie’s Phase IIb Study Design • Patients will be randomized in a 3:1 ratio of XIAFLEX to placebo and a 1:1 ratio to receive penile plaque modeling or no modeling. no Placebo D no XIAFLEX C yes Placebo B yes XIAFLEX A Targeted Number of Patients Plaque Modeling S

  31. Slide 31: Peyronie's Phase IIb Patient Reported Outcome (PRO)

    Peyronie’s Phase IIb Patient Reported Outcome (PRO) Peyronie’s Phase IIb Patient Reported Outcome (PRO) • Study is also designed to validate a proprietary Peyronie’s Patient Reported Outcome (PRO) questionnaire. • PRO will measure four domains of patients’ sexual quality of life, over a 36 week peri

  32. Slide 32: Market Research Performed – Peyronie's

    Market Research Performed – Peyronie’s Market Research Performed – Peyronie’s • Two rounds of quantitative primary research have been commissioned by Auxilium on XIAFLEX for Peyronie’s disease • A combined 575 Urologists have been interviewed to estimate market size (415 in U.S.; 160 in Europe) and

  33. Slide 33: At least 210,000 Peyronie's Candidates In U.S. and Europe Annually

    At least 210,000 Peyronie’s Candidates In U.S. and Europe Annually Patients Seeking Treatment ~475,000 Surgery Not Recommended ~365,000 Watchful Waiting ~160,000 Medical or Intralesional Therapy ~205,000 Surgery Recommended ~110,000 XIAFLEX Potential Candidates or 67% of Medical/ Surgical candidates

  34. Slide 34: XIAFLEX I.P. Position for Peyronie's Disease

    XIAFLEX I.P. Position for Peyronie’s Disease XIAFLEX I.P. Position for Peyronie’s Disease • U.S. Orphan Drug Exclusivity granted on March 12, 1996 for 7 years post approval • Market Exclusivity in EU could be extended to 11 years on approval of additional indication –Biosimilars would need to genera

  35. Slide 35: Testim 1% Testosterone Gel: Near-Term Growth Driver

    Testim ® 1% Testosterone Gel: Near-Term Growth Driver Executing on Opportunities

  36. Slide 36: Testim is the Fastest Growing Testosterone Replacement Therapy Gel

    Testim ® is the Fastest Growing Testosterone Replacement Therapy Gel Testim ® is the Fastest Growing Testosterone Replacement Therapy Gel • Proprietary, topical 1% testosterone gel – Once-a-day application – Favorable clinical and commercial profile • Recent study indicates 39% of U.S. males over 45

  37. Slide 37: 447% +30%

    447% +30% :

  38. Slide 38: Gels Fastest Growing TRT Segment

    Gels Fastest Growing TRT Segment Gels Fastest Growing TRT Segment Source: IMS data ($ in millions) Gel Patch Oral Injectables $35 $117 $200 $287 $340 $383 $449 $459 $399 $302 $210 $77 $59 $49 $499 $118 $568 Gel Segment Growth ($) Sep 2008 L12M: 23.4% Gel Segment Growth ($) Gel Segment Growth ($) Sep

  39. Slide 39: Testim quarterly net revenues and scripts: Established Track Record of Consistent Growth

    Testim ® quarterly net revenues and scripts Established Track Record of Consistent Growth $- $5 $10 $15 $20 $25 $30 $35 Net Revs TRX ® ($ in millions) Established Track Record of Consistent Growth Q3 2008 Net Revenues Y/Y Growth: +24.2% Q3 2008 Net Q3 2008 Net Revenues Revenues Y/Y Growth: Y/Y Growt

  40. Slide 40: We Believe Testim Is Driving Growth in Overall Gel Market

    We Believe Testim Is Driving Growth in Overall Gel Market Testim Share of TRx of Gel Market Source: IMS data gel market share of decile 8 - 10 PCPs (32.0%) gel market share of decile 8 - 10 Urologists (41.6%)

  41. Slide 41: Testim Patent Coverage

    Testim Patent Coverage U.S. • U.S. Patent # 7,320,968* covering method of use claims for Testim issued January 22, 2008; expires 2025 • Divisional application and continuations filed with U.S. PTO in late 2007 with a plan to protect additional inventions and seek additional claims • Upsher-Smith Lab

  42. Slide 42: 3Q08 Financial Results and 2008 Guidance

    3Q08 Financial Results and 2008 Guidance ($ Millions) Q3 ’08 9M’08 Guidance Revenues $32.6 $90.6 $120-125 R&D Expense $13.3 $39.9 $52-56 SG&A Expense $21.9 $65.1 $88-92 Net Loss ($10.1) ($34.1) ($44-48) Stock – Based Comp Expense $3.2 $8.1 $9-11 Cash & cash equivalents $46.4 3Q08 Financial Results a

  43. Slide 43: Strategic Priorities

    Strategic Priorities Strategic Priorities • Continue Development of XIAFLEX with a plan to: – 1) vigorously defending Testim and continuing to support the brand; – 2) filing of the XIAFLEX BLA for Dupuytren’s contracture, which we expect to achieve in early 2009; – 3) continuing our pre-launch comme

  44. Slide 44: Slide 44

Auxilium Pharmaceuticals — Investor Presentation (October 2008) on 6ix